Immunic, Inc. Cost of Revenue
Immunic, Inc. (IMUX) reported Cost of Revenue of $13.00 thousand for the 130-month period ending 2014-03-31, per its 10-Q filed 2014-05-28.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2014-05-28
- 2014-03-31: Cost of Goods and Services Sold 130 month $13.00K.
| Period end | Cost of Goods and Services Sold 130 month |
|---|---|
| 2014-03-31 | $13.00K 10-Q · filed 2014-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |